

## AMENDMENTS TO THE CLAIMS

### Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Currently amended) A method for inhibiting the growth of a *Staphylococcal* or *Haemophilus* species comprising contacting said species with a peptide comprising the sequence ~~KQRDSRSGYTAPTLV (SEQ ID NO:1), KKSHHPSSSEWGLNLT (SEQ ID NO:2), GRHRTSVPTDEVFIT (SEQ ID NO:3), KQRTSIRATEGCLPS (SEQ ID NO:4), RNHGTDRAATTIPPLS (SEQ ID NO:5), GSRGKHTFVRPTLVF (SEQ ID NO:6), FISYSSPSHMGARMR (SEQ ID NO:7) and/or VVFLSSRNSAVFTDF (SEQ ID NO:8).~~
- 2-9. (Canceled)
10. (Previously presented) The method of claim 1, wherein said species is a *Staphylococcal* species.
11. (Original) The method of claim 10, wherein said *Staphylococcal* species is *S. aureus*.
12. (Original) The method of claim 1, wherein said species a *Haemophilus* species.
13. (Original) The method of claim 12, wherein said *Haemophilus* species is *H. influenzae*.
14. (Original) The method of claim 13, wherein said *H. influenzae* species is non-typeable *H. influenzae*.
15. (Original) The method of claim 1, wherein said peptide is between 15 and about 50 residues in length.
16. (Previously presented) The method of claim 1, wherein said peptide is between 15 and about 25 residues in length.
17. (Original) The method of claim 1, wherein said peptide is 15 residues in length.

18. (Original) The method of claim 1, further comprising contacting said species with a chemopharmaceutical antibiotic.
19. (Currently amended) A method for treating a *Staphylococcal* or *Haemophilus* species bacterial infection in a subject comprising contacting said subject with a peptide comprising the sequence ~~KQRDSRSGYTAPTLV (SEQ ID NO:1),~~  
~~KKSHHPSSEWGLNLT (SEQ ID NO:2),~~ ~~GRHRTSVPTDEVFIT (SEQ ID NO:3),~~  
~~KQRTSIRATEGCLPS (SEQ ID NO:4),~~ ~~RNHGTDRAATTIPPLS (SEQ ID NO:5),~~  
~~GSRGKHHTFVRPTLVF (SEQ ID NO:6),~~ ~~FISYSSPSHMGARMR (SEQ ID NO:7)~~ and/or  
~~VVFLSSRNSAVFTDF (SEQ ID NO:8)~~ in an amount sufficient to inhibit the growth of bacteria *in vivo*.
- 20-28. (Canceled)
29. (Previously presented) The method of claim 19, wherein said *Staphylococcal* species is *S. aureus*.
30. (Canceled)
31. (Previously presented) The method of claim 19, wherein said *Haemophilus* species is *H. influenzae*.
32. (Original) The method of claim 31, wherein said *H. influenzae* species is non-typeable *H. influenzae*.
33. (Previously presented) The method of claim 19, wherein said peptide is between 15 and about 50 residues in length.
34. (Previously presented) The method of claim 19, wherein said peptide is between 15 and 25 residues in length.
35. (Previously presented) The method of claim 19, wherein said peptide is 15 residues in length.

36. (Currently amended) The method of claim 19, wherein said peptide is delivered ~~local~~locally or ~~regional~~regionally to a site of infection.
37. (Original) The method of claim 36, wherein said peptide is administered to a wound site.
38. (Original) The method of claim 36, wherein said peptide is administered topically.
39. (Previously presented) The method of claim 19, wherein said peptide is delivered systemically.
40. (Original) The method of claim 39, wherein said peptide is delivered via intravenous or intraarterial injection.
41. (Currently amended) The method of claim 19, further comprising administering to said subject a chemopharmaceutical antibiotic.
42. (Currently amended) A method for preventing a *Staphylococcal* or *Haemophilus* bacterial infection in a subject comprising contacting said subject with a peptide comprising the sequence ~~KQRDSRSGYTAPTLV (SEQ ID NO:1), KKSHHPSSEWGLNLT (SEQ ID NO:2), GRHRTSVPTDEVFIT (SEQ ID NO:3), KQRTSIRATEGCLPS (SEQ ID NO:4), RNHGTDTRATTIPPLS (SEQ ID NO:5), GSRGKHTFVRPTLVF (SEQ ID NO:6), FISYSSPSHMGARMR (SEQ ID NO:7) and/or VVFLSSRNSAVFTDF (SEQ ID NO:8)~~ in an amount sufficient to inhibit the growth of bacteria *in vivo*.
43. (Currently amended) A method for preventing *Staphylococcal* or *Haemophilus* bacterial growth in a solution comprising mixing said solution with a peptide comprising the sequence ~~KQRDSRSGYTAPTLV (SEQ ID NO:1), KKSHHPSSEWGLNLT (SEQ ID NO:2), GRHRTSVPTDEVFIT (SEQ ID NO:3), KQRTSIRATEGCLPS (SEQ ID NO:4), RNHGTDTRATTIPPLS (SEQ ID NO:5), GSRGKHTFVRPTLVF (SEQ ID NO:6), FISYSSPSHMGARMR (SEQ ID NO:7) and/or VVFLSSRNSAVFTDF (SEQ ID NO:8)~~ in an amount sufficient to inhibit the growth of bacteria in said solution.
44. (Currently amended) A method for preventing *Staphylococcal* or *Haemophilus* bacterial attachment or growth on an abiotic surface comprising coating said surface with a peptide comprising the sequence ~~KQRDSRSGYTAPTLV (SEQ ID NO:1),~~

~~KKSHHPSSEWGLNLT (SEQ ID NO:2), GRHRTSVPTDEVFIT (SEQ ID NO:3),~~  
~~KQRTSIRATEGCLPS (SEQ ID NO:4), RNHGTDRAATTIPPLS (SEQ ID NO:5),~~  
~~GSRGKHTFVRPTLVF (SEQ ID NO:6), FISYSSPSHMGARMR (SEQ ID NO:7) and/or~~  
~~VVFLSSRNSAVFTDF (SEQ ID NO:8)~~ in an amount sufficient to inhibit the growth of  
bacteria on said abiotic surface.

45. (Original) The method of claim 44, wherein said surface is part of a medical device.
46. (Original) The method of claim 45, wherein said medical device is a syringe, a stent, a catheter, fluid container, a pacemaker, or an implantable pump.
47. (Currently amended) A medical device, a surface of which is coated with a peptide comprising the sequence ~~KQRDSRSGYTAPTLV (SEQ ID NO:1),~~  
~~KKSHHPSSEWGLNLT (SEQ ID NO:2), GRHRTSVPTDEVFIT (SEQ ID NO:3),~~  
~~KQRTSIRATEGCLPS (SEQ ID NO:4), RNHGTDRAATTIPPLS (SEQ ID NO:5),~~  
~~GSRGKHTFVRPTLVF (SEQ ID NO:6), FISYSSPSHMGARMR (SEQ ID NO:7) and/or~~  
~~VVFLSSRNSAVFTDF (SEQ ID NO:8)~~ in an amount sufficient to inhibit the growth of  
Staphylococcal or Haemophilus bacteria *in vivo*.
48. (Original) The device of claim 47, wherein said medical device is a syringe, a stent, a catheter, fluid container, a pacemaker, a bandage, or an implantable pump.
49. (Original) The device of claim 47, wherein said medical device is coated with a second antibiotic agent.
- 50-55. (Canceled)
56. (Canceled)
57. (Currently amended) An isolated peptide of 15 to about 50 residues comprising the sequence ~~KQRDSRSGYTAPTLV (SEQ ID NO:1), KKSHHPSSEWGLNLT (SEQ ID~~  
~~NO:2), GRHRTSVPTDEVFIT (SEQ ID NO:3), KQRTSIRATEGCLPS (SEQ ID NO:4),~~  
~~RNHGTDRAATTIPPLS (SEQ ID NO:5), VVFLSSRNSAVFTDF (SEQ ID NO:6),~~  
~~GSRGKHTFVRPTLVF (SEQ ID NO:7), or FISYSSPSHMGARMR (SEQ ID NO:8).~~

58. (Currently amended) A method for identifying a *Staphylococcal* or *Haemophilus* bacterial receptor comprising:
- (a) providing a sample suspected of comprising a bacterial receptor;
  - (b) providing a peptide comprising the sequence ~~KQRDSRSGYTAPTLV (SEQ ID NO:1), KKSHHPSEWGLNLT (SEQ ID NO:2), GRHRTSVPTDEVFIT (SEQ ID NO:3), KQRTSIRATEGCLPS (SEQ ID NO:4), RNHGTDRATTIPPLS (SEQ ID NO:5), VVFLSSRNSAVFTDF (SEQ ID NO:6), GSRGKHTFVRPTLVF (SEQ ID NO:7), or FISYSSPSHMGARMR (SEQ ID NO:8);~~
  - (c) contacting said sample with said peptide; and
  - (d) identifying a receptor that binds to said peptide.
59. (Original) The method of claim 58, wherein said sample is a whole bacterium.
60. (Original) The method of claim 58, wherein said sample is a bacterial cell wall.
61. (Original) The method of claim 58, wherein said peptide is fixed to a support.
62. (Original) The method of claim 61, wherein said support is a filter, a column, a bead, a dipstick or a gel.
63. (Original) The method of claim 58, further comprising degradative sequencing of said identified receptor.
64. (Original) The method of claim 63, further comprising designing a degenerative probe based on the sequence of said identified receptor.
65. (Original) The method of claim 64, further comprising using said degenerative probe to identify the gene encoding said identified receptor.